Brief: Citius Pharmaceuticals Inc - Regains Compliance With Nasdaq Listing Rule 5550(A)(2)
20/12/2024 21:51
Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS INC - REGAINS COMPLIANCE WITH
NASDAQ
LISTING RULE 5550(A)(2)
Source text: ID:n0001213900-24-111212
Further company coverage: CTXR.O
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules